The activity of voriconazole against Sandida albicans and Sandida krusei
Over the past decade, the number of Candida spp. Resistant to fluconazole has increased. Voriconazole is a relatively recently used antifungal drug which (according to previous studies) is active against fluconazole-resistant strains of Candida spp.
American researchers led by J.K. Lee suggested that the fluconazole-resistant strains of Candida albicans and Candida krusei may be susceptible to voricoazole. For the period from 1984 to 1995. In 205 strains of C. albicans and since 1995 in C. albicans and C. krusei (resistance to fluconazole), the sensitivity to amphotericin B has been studied, itraconazole, 5-flucytosine, ketoconazole, fluconazole and Voroconazole. Three strains of C. albicans and 26 C. krusei had MICs of fluconazole greater than 20 mg / ml and were considered to be resistant to fluconazole. Of these, in 28 strains, the mean MIC of voriconazole was found to be 0.78 mg / L, and the MIC of amphotericin B = 0.98 mg / L. Only one strain C.krusei was resistant to voriconazole (MPC = 5 mg / L). Among 29 pathogens, there were 10 amphotericin B resistant strains of C. krusei (BMD greater than 2 mg / l), but all were susceptible to voriconazole (BMD less than 2.5 mg / l).
According to the researchers, the data obtained make it possible to recommend voriconazole for the treatment of infections caused by fluconazole and the amphotericin B resistant strains of C. albicans and C. krusei .